Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As we establish more sites and generate higher sample volumes, we expect our authorized sites to offer more predictable and higher-margin revenue while reducing sample delivery times for researchers globally |
| I'm pleased to report another solid quarter marked by consistent progress on our commercial initiatives and increased operational rigor throughout the organization |
| As we noted earlier in the year, we continue to expect full year 2023 gross margins in the mid-40% range and expect our margin profile to improve long term from our combined distributed solution and future royalty revenues |
| And so we're feeling good about that |
| This joint proteomics product will combine Illumina's market-leading installed base and commercial force with the breadth and depth of the SomaScan assay to deliver differentiated insights to researchers across a wide range of customer segments |
| And we remain excited for our future as part of the combined company with Standard BioTools |
| I would say most of the -- we're seeing fantastic growth in both customer segments, but we're really starting to accelerate and penetrate more deeply in the biopharma |
| We believe the combined business will be positioned to meaningfully accelerate our path to probability, and we continue to expect the merger to close in the first quarter of 2024 |
| And we look forward to another strong quarter and closing the merger with Standard BioTools |
| Now before I turn the call over to Eliot Lurier, our Interim Chief Financial Officer, I'd like to reiterate that we are making strong progress towards our business objectives |
| Following the 7K SomaScan offering, our prior core technology, the 11K SomaScan platform is expected to give researchers a considerable edge in the discovery of biomarkers and drug targets for translational medicine |
| Our third quarter results reflect substantial progress across ongoing expense reduction initiatives |
| Given our progress, we are raising our full year 2023 revenue expectations to $82 million to $85 million from the prior range of $80 million to $84 million |
| In particular, I think [indiscernible] so what we're seeing is really more broad-based growth as we extend our [indiscernible] in Europe historically, we're seeing really nice uptick in [indiscernible] |
| So activity level is great and [indiscernible] |
| Our underlying third quarter performance was driven by increasing adoption of the SomaScan platform as well as an increase in revenue through our authorized sites |
| Finally, we are incredibly excited to announce the commercial launch of the 11K SomaScan assay |
| It expands our commercial reach with cross-selling opportunities and complementary offerings |
| And having a broader view of the human proteome provided by this expanded platform gives our customers more opportunities to make unique and novel biological discoveries |
| The merger establishes a leading platform of multi-omic technologies to power research insights across a broad and growing market while expediting SomaLogic's path to scale and cash flow breakeven |
| And I think you guys beat the quarter by about $1.5 million relative to The Street and raised the midpoint of the guide |
| This improves accuracy with fewer, smaller samples, which is often critical in population studies with limited sample volumes |
| Excluding $22.3 million in royalty revenue in the third quarter of 2022 from NEB, our revenue increased by 14% year-on-year |
| Ending with our full year outlook, as Adam mentioned, we are raising our 2023 revenue guidance to $82 million to $85 million |
| Product revenue associated with our authorized site strategy was up close to $2.5 million versus Q3 '22 and up $0.5 million or 17% sequentially from Q2 of this year |
| Excluding the NEB royalty revenue in the third quarter of 2022, gross margin increased by 7.4% year-on-year |
| So [indiscernible] some of those new sites that we've gotten up and running, but [indiscernible] one of the things we've tried to do over the last several quarters is selecting great partner |
| Despite a challenging macroeconomic environment, we achieved third quarter revenue of $22 million, reflecting 14% year-over-year growth when excluding nonrecurring licensing revenue that we received in the third quarter of last year |
| As early innovators in this space, we know that the discovery and development of disruptive therapeutics benefit substantially from a more complete view of the proteome |
| last week, I had the opportunity to speak to a number of prospective customers who are really excited about being able to leverage their Illumina NGS instrumentation to gain deeper proteomic insights in their research |
| Statement |
|---|
| Gross margin for the third quarter of 2023 was 47.2%, a decrease from 72% in the prior year period |
| Revenue for the 3 months ended September 30, 2023, was $22 million as compared to $41.7 million in the third quarter of 2022, a 47% year-over-year decline on a GAAP basis |
| Our cash burn in the quarter was $20 million, reflecting a significantly sequential decrease as we implement greater spending control |
| Accounting for the NEB royalty in Q3 '22, the adjusted EBITDA would have been a loss of $52.5 million |
| Adjusted EBITDA for the third quarter of 2023 was a loss of $20.1 million compared to an adjusted EBITDA loss of $30.2 million in the third quarter of 2022 |
| Can you repeat the question? Kyle Boucher Yes, we might be having some technical difficulties here |
| Total operating expenses for the third quarter of 2023 were $38.5 million, a 46% decrease from $70.7 million in the third quarter of 2022 |
| I'm having trouble hearing, but I think the audio [indiscernible] |
Please consider a small donation if you think this website provides you with relevant information